Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03205696 · ClinicalTrials.gov registry record
Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection
A clinical trial, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 101
- Enrollment target
NCT03205696: Completed study, sponsored by University of California, Los Angeles.
NCT03205696 is a clinical trial that has completed, run by University of California, Los Angeles. The registered enrollment target is 101 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03205696 has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 101 participants
- Enrollment target
Study Summary
This is a strategic prospective cohort study which will measure the effects of early intensive antiretroviral therapy (ART) on the establishment and persistence of HIV-1 reservoirs and HIV-1-specific immunity in acutely /recently HIV infected youth aged 12 to 24 years as compared to newly diagnosed youth with established infection \> 6 months. Participants with newly diagnosed acute /recent HIV-1 infection will be offered enrollment into the study with immediate initiation of ART which is the current standard of care.
Primary Outcome
To compare the amount of cell-associated HIV-1 DNA (CAHD) in 5 million blood-derived CD4+ T-cells and total PBMC (assayed by quantitative ddPCR \[qPCR\]) at 12 months in participants who initiated ART in Fiebig I/II versus Fiebig III/IV versus Fiebig V and those with newly diagnosed but established/chronic HIV infection with sustained suppression of plasma HIV-1 RNA.
Interventions
- DRUG Antiretrovirals
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2023-11-30 |
What the finished NCT03205696 record still lists
NCT03205696 is an observational study that tracks outcomes without assigning an intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Antiretrovirals is the first listed.
NCT03205696 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03205696 about?
NCT03205696 is a clinical study titled "Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection". This is a strategic prospective cohort study which will measure the effects of early intensive antiretroviral therapy (ART) on the establishment and persistence of HIV-1 reservoirs and HIV-1-specific immunity in acutely /recently HIV infected youth aged 12 to 24 years as compared to newly diagnosed ...
What is the current status of trial NCT03205696?
This trial is currently completed. The enrollment target is 101 participants. The study started on 2017-08-01. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT03205696?
The interventions under investigation include: Antiretrovirals (DRUG).
Who is sponsoring clinical trial NCT03205696?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI